Personalised to support your treatment decisions
Gilead Sciences, Inc.announced that the European Commission has granted conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Boehringer Ingelheim have announced the results of a sub-group analysis from the CAROLINA cardiovascular outcome trial focusing on Asian adults with type 2 diabetes mellitus and elevated cardiovascular risk.
CSL Behring announced that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for Idelvion [albutrepenonacog alfa, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP], CSL Behring’s novel, long-acting recombinant albumin fusion protein for treating haemophilia B.
You may be interested in...
6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment
The successful biannual ESH Conferences on acute myeloid leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation.
The Haematological Tumour Microenvironment and its Therapeutic Targeting 2021
This workshop brings together a constantly growing and international community of researchers, physicians and physician scientists, as well as biologists and physicians in training and corporate representatives, whose present or future work is focused on the tumor microenvironment in the haematological malignancies.